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Surgical operation is the key element of treatment 
in patients with ovarian cancer. It enables us to make 
histological diagnosis, assess the clinical stage, exert an 
immediate palliative effect, and decrease the tumour’s 
volume, which together increase the effectiveness of 
anticancer drugs [1]. Despite controversies regarding 
tolerability of expansive cytoreductive operations, 
radicality of surgery is — after staging according to 
the FIGO (Fédération internationale de gynécologie et 
d’obstétrique) system — the most important prognostic 
factor in patients with ovarian cancer [2, 3]. It is already 
known that independently of the mentioned factors the 
burden of peritoneal disease and preoperative tumour 
volume influence the survival [4, 5]. Similarly, the volume 
of free peritoneal fluid correlates with the intensity of 
cancer as well as the probability of achieving complete 
cytoreduction [6–8]. Recently, numerous operation’s 
protocols for ovarian cancer patients do not include such 
important data, which makes the treatment even more 
difficult, especially when the treatment is conducted in 
another clinical centre. Thus, the Board of the Polish 
Gynaecological Oncology Society proposes to unify and 
possibly simplify the operation’s protocol for all sites 
leading surgical treatment of ovarian cancer patients. 
The value of detailed description, localisation, and 
size of neoplastic lesions revealed during primary opera-
tion (exploratory laparotomy as well as diagnostic lapa-
roscopy) could not be overestimated during planning of 
further treatment of those patients. The decision about in-
terval cytoreductive surgery or its abandonment, diagnosis 
of signs and symptoms of ovarian cancer patients, use of 
adjuvant and supportive therapy, as well as potential deci-
sions regarding a secondary cytoreductive procedure, are 
based on this information. Because intraoperative assess-
ment of the magnitude of residual cancer is in many cases 
underestimated, it seems expedient to perform computed 
tomography (CT) every 4–6 weeks during postoperative 
follow-up [9]. Of note, the results of CT imaging are cur-
rently essential for qualification of patients with advanced 
ovarian cancer to bevacizumab therapy, according to the 
Ministry of Health drug program [10]. 
The proposed protocol is readable and simple to 
complete. It allows the provision, in a very simple way, 
of comprehensive information regarding all peritoneal 
fields that could be potentially affected by cancer. Based 
on this, patients with ovarian cancer after suboptimal 
surgical treatment have a chance for well prepared, 
interval cytoreductive surgery in a reference centre as 
well optimal adjuvant treatment.
Additionally, a full version of the protocol is avail-
able electronically at www.ptgo.pl and as an App Store 
application (Protokół leczenia PTGO), and shortly it will 
be available in hard copy in all obstetrics and gynaeco-
logy wards in Poland. 
On behalf of the Board 
of the Polish Gynaecological Oncology Society 
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Board Secretary
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